Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype
characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia,
defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes
mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect
in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia
with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences
of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.